Our therapeutic approach

Allergen immunotherapy (AIT) is the only therapeutic class capable of modifying disease progression and potentially preventing the onset of the disease. AIT consists in administering allergens by sublingual or subcutaneous route, thus allowing the reorientation of the immune responses of patients towards allergen-specific tolerance induction.

Precision medicine for better patient care

Stallergenes Greer is committed to furthering precision medicine and personalised AIT treatments to address unmet medical needs for patients with allergies.

With precision medicine, Stallergenes Greer identifies the mechanisms of allergic response to develop best in class diagnostic tools and personalised allergen immunotherapy treatments.

We are committed to delivering unparalleled patient care through our extensive product portfolio which covers all administration (subcutaneous and sublingual) routes and personalised treatment solutions which meet the needs of both individual patient-profiles and the medical community.

A high level of scientific expertise

Each allergen source contains several molecules which are recognised by the immune system as allergens and will trigger an allergic reaction.

Allergens are large, complex molecules composed of a multitude of atoms. Working with large molecules requires a high level of scientific expertise and state-of-the-art technologies to characterise and quantify allergens. Specific processes are required due to both the complexity of the molecules and their biological nature.

A focused approach to innovation

At Stallergenes Greer, we have been working with allergens for more than 100 years. We aim to develop treatments that address the unmet needs of a growing number of allergy patients around the world. We focus our efforts on allergen characterisation as well as on optimal approaches to deliver allergens to the immune system.

Our long-standing work on the mechanisms of action of AIT has enabled us to identify candidate biomarkers which correlate with clinical outcomes observed in double-blind placebo-controlled AIT trials. These candidates could be used either as predictive or follow-up biomarkers in line with our commitment to explore further allergy diagnosis and treatment personalisation.